Lab21 ramps up KRAS and EGFR testing capacity
Lab21, a UK-based provider of health care diagnostic products and services, has launched K-RAS gene mutation and epidermal growth factor receptor mutation testing services for its international customers.
The company has seen the demand for K-RAS testing increase 10-fold since its launch at the beginning of the year and, with recent investment in people and systems, Lab21 is set to ramp capacity by 10-fold again to cope with the projected demand.
Recent drug licences for targeted cancer therapies such as ImClone/Bristol-Myers Squibb's Erbitux (cetuximab) and Amgen's Vectibix (panitumumab) require analysis of the KRAS gene in the tumor to assess if a patient will respond to the therapy. Through its international logistics function, Lab21 is now able to assist UK and international health care providers in screening patients for this mutation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze